Emily M. Leproust Sells 1,654 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,654 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $74,264.60. Following the completion of the sale, the chief executive officer now directly owns 673,064 shares in the company, valued at $30,220,573.60. This trade represents a 0.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Twist Bioscience Stock Down 2.1 %

TWST opened at $48.17 on Friday. The firm’s fifty day simple moving average is $45.58 and its two-hundred day simple moving average is $46.74. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -13.38 and a beta of 1.82.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TWST shares. Scotiabank increased their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. Barclays dropped their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. TD Cowen reissued a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Evercore ISI raised their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.90.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its holdings in shares of Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after acquiring an additional 82,953 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new position in Twist Bioscience in the 3rd quarter valued at $3,302,000. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience in the 3rd quarter valued at $95,000. Franklin Resources Inc. boosted its stake in Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock worth $11,756,000 after purchasing an additional 8,308 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience during the third quarter worth $34,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.